Latest news
Why Sarepta Therapeutics (SRPT) Is Up 12.9% After Cutting 2026 Guidance And Naming A New CEO - simplywall.stsimplywall.st · Mon, 10 Aug 2026 05:32:51 GMTSarepta Therapeutics, Inc. Revenue Breakdown – BX:AB3A - TradingViewTradingView · Sun, 09 Aug 2026 01:01:58 GMTSarepta Therapeutics Inc at TD Cowen Healthcare Conference Transcript - GuruFocusGuruFocus · Sat, 08 Aug 2026 19:32:01 GMTSarepta Shares Rise As Company Begins Enrollment In Gene Therapy Safety Enhancement Study - StocktwitsStocktwits · Sat, 08 Aug 2026 11:59:18 GMTSarepta Stock Dips After Hours: DMD Drug Blow And CEO Exit Eclipse Q4 Revenue Beat - StocktwitsStocktwits · Fri, 07 Aug 2026 17:26:02 GMTState Street (NYSE: STT) discloses 8.4% Sarepta Therapeutics ownership via Schedule 13G - Stock TitanStock Titan · Fri, 07 Aug 2026 14:55:22 GMTSarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - StocktwitsStocktwits · Fri, 07 Aug 2026 12:06:44 GMTSarepta Therapeutics (SRPT) Stock Rally Hinges On Profit Progress And Revenue Drop - SahmSahm · Fri, 07 Aug 2026 07:00:00 GMT